# A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

> **NCT02289950** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 332 (actual)

## Conditions studied

- Platinum-Sensitive Ovarian Cancer in First Relapse

## Interventions

- **DRUG:** Farletuzumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02289950
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-19
- **Primary completion:** 2019-05-31
- **Final completion:** 2020-08-13
- **Target enrollment:** 332 (ACTUAL)
- **Last updated:** 2021-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289950, "A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02289950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*